From DCAT Value Chain Insights (VCI)
The European Medicines Verification Organization (EMVO) is a Luxembourgish non-profit organization representing stakeholder groups united in securing the legal supply chain from falsified medicines, has finalized its contract negotiations with three partners that will be the preferred providers to implement the repositories system in compliance with the European Union's Falsified Medicines Directive. The founding members of EMVO are the European Federation of Pharmaceutical Industries and Associations, the European Generic and Biosimilar medicines Association, the Pharmaceutical Group of the European Union, the European Association of Pharmaceutical Full-line Wholesalers, and the European Association of Euro-Pharmaceutical Companies.
The repositories system will allow the verification for authentication of medicines in Europe. EMVO was formed in February 2015 by these five stakeholder groups to lead in the creation of this system.
The EMVO has designed a model that ensures a practical and cost-effective implementation of these repositories to minimize the burden of national stakeholder organisation or NMVOs which eventually will be responsible for the establishment and management of the systems. This blueprint model includes a support plan or implementation package and a short list of preferred service providers.
The EMVO has concluded a fruitful negotiation with three valued partners: Aegate Holdings Limited, Arvato Systems GmbH and Solidsoft Reply. NMVOs will have the opportunity to select a service provider best suited to establish a repository system in their member state.
Source: European Generic and Biosimilar medicines Association
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription